简介: [摘要 ]目的 探讨血栓通联合低分子肝素钙在治疗短暂性脑缺血发作中的效果。方法 选取 2018年 3月~ 2019年 2月我院收治的 45例短暂性脑缺血发作患者临床资料,依据治疗措施不同进行分组,对照组 15例和联合治疗组 30例,观察两组短暂性脑缺血发作患者治疗前后活化凝血活酶时间( ATPP)、血小板计数( PLT)、凝血酶原时间( PT)、临床治疗总有效率情况。结果 两组短暂性脑缺血发作患者治疗前 ATPP、 PLT、 PT均无明显差异( P>0.05),对照组治疗前后 ATPP、 PLT、 PT均无明显差异( P>0.05),观察组治疗后 ATPP、 PT均高于治疗前, PLT均低于治疗前,观察组治疗后 ATPP、 PT均高于对照组, PLT均低于对照组,观察组短暂性脑缺血发作患者临床治疗总有效率均高于对照组,差异均有统计学意义( P<0.05)。结论 血栓通联合低分子肝素钙在治疗短暂性脑缺血发作,临床效果明显,预后良好,值得临床推广应用。 [关键词 ]血栓通;低分子肝素钙;短暂性脑缺血发作;效果 [Abstract] Objective To explore the effect of Xueshuantong combined with low molecular weight heparin calcium in the treatment of transient ischemic attack. Methods the clinical data of 45 patients with TIA from March 2018 to February 2019 were selected and divided into two groups according to different treatment measures. 15 patients in the control group and 30 patients in the combined treatment group were observed before and after the treatment. The activated thromboplastin time (atpp), platelet count (PLT), prothrombin time (PT) and clinical treatment of the two groups were always Efficiency. Results there was no significant difference in atpp, PLT and Pt between the two groups before and after treatment (P > 0.05). There was no significant difference in atpp, PLT and Pt between the two groups before and after treatment (P > 0.05). After treatment, atpp and Pt in the observation group were higher than before treatment, PLT were lower than before treatment. After treatment, atpp and Pt in the observation group were higher than those in the control group, PLT were lower than those in the observation group The difference was statistically significant (P < 0.05). Conclusion Xueshuantong combined with low molecular weight heparin calcium in the treatment of transient ischemic attack, the clinical effect is obvious, the prognosis is good, it is worth clinical application.
简介:【摘要】目的 观察脑梗死患者采取阿司匹林联合口服硫酸氢氯吡格雷治疗的安全性和有效性。方法 本次试验将我院 2018年 8月至 2019年 9月期间收治的 68例脑梗死患者作为研究对象,按照随机抽签方式将其分为两组,各 34例,观察组与对照组分别采取阿司匹林与口服硫酸氢氯吡格雷联合治疗与单项阿司匹林治疗,比较两组患者治疗前后 NIHSS评分。结果 治疗前,两组研究对象 NIHSS评分对比,无显著差异( P> 0.05);治疗后,观察组 NIHSS评分显著低于对照组,组间数据对比,差异性显著( P<0.05)。结论 脑梗死患者采取阿司匹林与口服硫酸氢氯吡格雷联合治疗,能够提升治疗效果,缓解患者不良症状,改善患者神经缺损功能,提升患者生存质量,降低不良反应发生率,确保治疗安全性,获取良好的预后效果,有临床实践价值。
简介: 【摘要】目的:分析双黄连注射剂对急性上呼吸道感染( AURI)的疗效情况。方法: 2017年 1月 -2018年 9月选取我院 86例 AURI患者,按照患者治疗方法不同,将其分为对照组(应用利巴韦林) 43例及观察组(应用双黄连注射剂) 43例,比较两组临床疗效及副反应发生率。结果:观察组临床总有效率为 95.35%,明显高于对照组 81.40%( P<0.05)。两组副反应发生率对比, P>0.05,差异无统计学意义。结论:采用双黄连注射剂治疗 AURI具有安全性佳、疗效好等优点。 【关键词】双黄连注射剂; AURI;疗效;分析 [Abstract] Objective: to analyze the therapeutic effect of Shuanghuanglian Injection on acute upper respiratory tract infection (AURI). Methods: from January 2017 to September 2018, 86 cases of AURI in our hospital were selected. According to different treatment methods, they were divided into control group (ribavirin) 43 cases and observation group (Shuanghuanglian injection) 43 cases. The clinical efficacy and incidence of side effects of the two groups were compared. Results: the total clinical effective rate of the observation group was 95.35%, which was significantly higher than that of the control group (81.40%) (P < 0.05). There was no significant difference between the two groups (P > 0.05). Conclusion: Shuanghuanglian injection is safe and effective in the treatment of AURI.
简介:(武汉市结核病防治所湖北武汉430030)摘要目的观察胸腔内注入肝素治疗结核性包裹性胸膜炎的疗效。方法69例结核性包裹性胸膜炎患者随机分为治疗组(35例)与对照组(34例)。治疗组每次充分引流后注射肝素6250U+生理盐水20ml,对照组不注药。两组抗结核方案均为2HREZ/4HR。结果治疗组显效率34.3%,对照组为8.8%,两者有显著性差异(P﹤0.01)。治疗组总有效率91.4%,对照组为79.4%,两者有显著性差异(P﹤0.01)。治疗2月后,B超观察治疗组胸膜厚度3.8±1.3mm,对照组为6.5±2.9mm,两者有显著性差异(P﹤0.01)。治疗组肺功能FVC%为(89.8±1.7)%,对照组(76.5±1.6)%(P﹤0.05);治疗组FEV1/FVC%为(85.2±2.9)%,对照组为(74.6±2.5)%,两者差异亦有显著性(P﹤0.05)。结论胸腔内注射肝素能减少胸膜肥厚粘连,改善肺功能,药物安全性好,是一项有效的辅助治疗措施。